LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)

Background: There is ongoing controversy regarding the outcome of COVID-19 in cancer patients This is one of few registries on the impact of COVID-19 in cancer patients in a country severly affected by the pandemic Methods: This cohort study is collecting data on symptomatic Sars-CoV-2 infected patients with a cancer diagnosis from 23 Swiss sites, starting March 1, 2020 The main objective of the study is to assess the outcome of COVID-19 infection in patients with solid and hematological malignancies, while the main secondary objective is to define prognostic factors of COVID-19 outcome Results: With a cutoff date of July 16, 2020, 357 patients with a diagnosis of cancer and symptomatic COVID-19 were included into this first analysis The most frequent malignancies were breast in 63 cases (18%), lung in 40 cases (11%), prostate cancer in 24 cases (7%) and myeloma in 16 cases (5%), with 104 (38%) patients having non-curative disease Anticancer treatment within 3 months prior to the diagnosis of COVID-19 included chemotherapy in 65 patients (18%), targeted therapy in 54 patients (15%), steroids in 39 (11%), checkpoint inhibitors in 22 (6%) or no anticancer treatment in 155 patients (43%) 230 patients (65%) were hospitalized for COVID-19 or were already in hospital;167 of the hospitalized patients (73%) required oxygen treatment, 43 patients (19%) intensive care, 31 (14%) invasive ventilation 63 patients died from COVID-19 infection, resulting in a mortality rate of 18% Significant risk factors for death included age ≥65 versus \u003c65 (HR 5 84, p\u003c0 001) and non-curative versus curative disease (HR 2 34, p= 01) Neither male versus female gender (HR 1 59, p=0 12), type of cancer, geographic region, chemotherapy (HR 1 31, p=0 44), cardiovascular disease (HR 2 25, p=0 09) nor pulmonary comorbidity (HR 0 93, p=0 86) were significant risk factors for death Conclusions: We found a COVID-19 mortality rate in real-world cancer patients in a country with a decentralized, high-quality health care system that is substantially higher than in all COVID-19 infected patients in Switzerland (18% versus 5%) The rate of hospitalization and intensive care from COVID-19 in cancer patients is substantial Legal entity responsible for the study: Swiss Clinical Cancer Research Group Funding: Swiss Clinical Cancer Research Group Disclosure: All authors have declared no conflicts of interest